The global D-dimer testing market was estimated at USD 1.86 billion in 2024 and is projected to reach USD 2.46 billion by 2030, growing at a CAGR of 4.5% from 2025 to 2030. The market’s expansion is primarily driven by the rising prevalence of blood clotting disorders, particularly venous thromboembolism (VTE), which has become a major public health concern worldwide. According to the Centers for Disease Control and Prevention (CDC), approximately 5% to 8% of the U.S. population carries genetic risk factors that predispose them to VTE. Moreover, the burden of this condition is significant, with nearly 900,000 people affected annually in the United States, leading to 60,000 to 100,000 deaths every year. Such alarming statistics underscore the critical role of D-dimer testing in timely and accurate diagnosis, enabling healthcare providers to identify at-risk patients, reduce complications, and improve survival outcomes.

A notable trend shaping the market is the transition from traditional laboratory-based testing to point-of-care (POC) D-dimer testing. The growing adoption of POC solutions is attributed to their convenience, rapid turnaround time, and clinical efficiency. Unlike conventional laboratory methods, which can be time-consuming, POC D-dimer tests allow healthcare professionals to perform assessments in diverse clinical settings including emergency departments, outpatient clinics, and primary care facilities thus enabling faster decision-making and more effective patient management. By 2023, the healthcare industry increasingly emphasized POC diagnostic solutions, highlighting their growing importance in streamlining workflows, reducing hospital admissions, and improving patient care pathways.

Key Market Trends & Insights:

  • Regional Outlook: North America led the market, accounting for a 33.8% share in 2024, supported by high awareness of thrombotic conditions, advanced healthcare infrastructure, and strong adoption of diagnostic innovations. The Asia Pacific region is projected to record the fastest CAGR of 6.1%, driven by rising healthcare expenditure, growing patient awareness, and expanding diagnostic networks in emerging economies.
  • By Product: The reagents and consumables segment dominated the market in 2024, holding a 65.1% share, as recurring demand for these products drives consistent revenue. The analyzers segment is projected to expand at the fastest CAGR of 4.8%, supported by technological advancements in automated systems.
  • By Test Type: Clinical laboratory tests accounted for the largest share at 62.0% in 2024, reflecting their reliability and widespread use in hospital settings. Meanwhile, POC tests are projected to grow at the fastest CAGR of 4.8%, as healthcare systems increasingly favor decentralized testing solutions.
  • By End Use: Hospitals represented the leading end-use segment, with a 36.8% market share in 2024, owing to their large patient base and advanced diagnostic facilities. Diagnostic centers are expected to grow at the fastest CAGR of 5.0%, reflecting rising demand for accessible and cost-efficient diagnostic services.
  • By Method: The Enzyme-linked Immunosorbent Assay (ELISA) segment accounted for the largest share of 41.6% in 2024, given its proven accuracy and use as a gold standard in diagnostic testing. The Fluorescence Immunoassays (FIA) segment is projected to expand at the fastest CAGR of 5.4%, driven by advancements in high-sensitivity assays.
  • By Application: Deep Vein Thrombosis (DVT) remained the largest application area, contributing 37.4% of the market share in 2024, owing to the high incidence of this condition. The Disseminated Intravascular Coagulation (DIC) segment is expected to record the fastest CAGR of 5.5%, reflecting its increasing clinical recognition and need for early detection.

Order a free sample PDF of the D-dimer Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

  • 2024 Market Size: USD 1.86 Billion
  • 2030 Projected Market Size: USD 2.46 Billion
  • CAGR (2025-2030): 4.5%
  • North America: Largest market in 2024
  • Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some key companies operating in the market include Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche The competitive landscape of the D-dimer testing market is shaped by the presence of leading diagnostic companies such as Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd; Siemens Healthcare; and BIOMÉRIEUX. These players are actively investing in R&D, strategic partnerships, product launches, and technological innovations to enhance diagnostic efficiency and accuracy.

  • Hoffmann-La Roche Ltd offers advanced D-dimer assays that improve the detection of fibrin degradation products, helping clinicians make precise diagnoses of thromboembolic diseases and improving patient management outcomes.
  • BIOMÉRIEUX has built strong expertise in diagnostic solutions, notably with its VIDAS® D-Dimer Exclusion test, which has been validated through extensive clinical studies as a reliable reference tool for excluding VTE. This test has gained significant traction due to its proven accuracy and clinical relevance.
  • Other global players continue to expand their product portfolios, focusing on automation, sensitivity, and POC innovations to remain competitive in an evolving healthcare landscape.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global D-dimer testing market is set to expand steadily, driven by the rising prevalence of blood clotting disorders such as VTE, growing awareness of early diagnosis, and the increasing adoption of point-of-care testing for faster clinical decision-making. With North America leading in market share and Asia Pacific emerging as the fastest-growing region, demand is expected to accelerate across both developed and developing healthcare systems. Continuous innovation by key players, advancements in testing methods, and the shift toward more accessible, rapid, and accurate diagnostic solutions will further strengthen the role of D-dimer testing as a critical tool in modern healthcare.